Last reviewed · How we verify
VeraCept
VeraCept is a medication that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).
VeraCept is a medication that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Used for Congenital adrenal hyperplasia, Cushing's syndrome.
At a glance
| Generic name | VeraCept |
|---|---|
| Sponsor | Sebela Women's Health Inc. |
| Drug class | 11β-HSD2 inhibitor |
| Target | 11β-HSD2 |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
This inhibition leads to a decrease in the conversion of cortisone to cortisol, resulting in a reduction of cortisol levels in the body. This can be beneficial for patients with conditions such as Cushing's syndrome or congenital adrenal hyperplasia.
Approved indications
- Congenital adrenal hyperplasia
- Cushing's syndrome
Common side effects
- Hypokalemia
- Fatigue
- Nausea
- Headache
- Dizziness
Key clinical trials
- Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception (PHASE2)
- Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS (PHASE3)
- A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs) (PHASE3)
- Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VeraCept CI brief — competitive landscape report
- VeraCept updates RSS · CI watch RSS
- Sebela Women's Health Inc. portfolio CI